Photosensitizing medication use and risk of skin cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 11, 2010, Pages 2942-2949

  Kaae, Jeanette ^a   Boyd, Heather A ^a   Hansen, Anne V ^a   Wulf, Hans Christian ^b   Wohlfahrt, Jan ^a   Melbye, Mads ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMIODARONE; ATENOLOL; BENDROFLUMETHIAZIDE; BUMETANIDE; CAPTOPRIL; CARBAMAZEPINE; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; ENALAPRIL; ETRETIN; FUROSEMIDE; IBUPROFEN; INDOMETACIN; ISOTRETINOIN; KETOCONAZOLE; METFORMIN; METHOTREXATE; METHYLDOPA; PHOTOSENSITIZING AGENT; SIMVASTATIN; SOTALOL; TETRACYCLINE; TOLBUTAMIDE; VALPROIC ACID; VERAPAMIL;

ARTICLE; BASAL CELL CARCINOMA; CANCER RISK; CAUSAL ATTRIBUTION; DRUG INDUCED CANCER; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; MERKEL CELL TUMOR; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SKIN CANCER; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION;

DENMARK; HUMANS; PHOTOSENSITIVITY DISORDERS; PRESCRIPTION DRUGS; REGISTRIES; RISK FACTORS; SKIN NEOPLASMS;

EID: 78549274091     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0652     Document Type: Article

References (30)

1. Gould JW, Mercurio MG, Elmets CA. Cutaneous photosensitivity diseases induced by exogenous agents. J Am Acad Dermatol 1995;33:551-73.
2. Stern RS. Photocarcinogenicity of drugs. Toxicol Lett 1998;102-103:389-92.
3. Bellaney GJ, Proby CM, Hawk JL. Likely photosensitizing agents available in the United Kingdom - an update. Clin Exp Dermatol 1996;21:14-6.
4. Jensen AO, Thomsen HF, Engebjerg MC, Olesen AB, Sorensen HT, Karagas MR. Use of photosensitising diuretics and risk of skin cancer: a population-based case-control study. Br J Cancer 2008;99:1522-8.
5. Karagas MR, Stukel TA, Umland V, et al. Reported use of photosensitizing medications and basal cell and squamous cell carcinoma of the skin: results of a population-based case-control study. J Invest Dermatol 2007;127:2901-3.
6. Epstein JH. Phototoxicity and photoallergy. Semin Cutan Med Surg 1999;18:274-84.
7. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. Cancer 1994;73:2759-64.
8. Lindelof B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999;141:108-12.
9. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001;44:755-61.
10. Ferguson J. Fluoroquinolone photosensitization: a review of clinical and laboratory studies. Photochem Photobiol Sci 1995;62:954-8.
11. Medstat, Danish Medicines Agency. Sales of medicinal products within the different ATC groups in the primary healthcare sector, 2004-2008. Available from: http://www.laegemiddelstyrelsen.dk/db/filarkiv/6687/Kapitel2.pdf.
12. Friis S, Sorensen HT, Mellemkjaer L, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 2001;92:2462-70.
13. Grau M, Baron J, Langholz B, et al. Effect of NSAIDs on the recurrence of nonmelanoma skin cancer. Int J Cancer 2006;119:682-6.
14. Sorensen HT, Friis S, Norgard B, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003;88:1687-92.
15. Preston DS, Stern RS. Nonmelanoma cancers of the skin. N Engl J Med 1992;327:1649-62.
16. Gallagher RP, Hill GB, Bajdik CD, et al. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. Arch Dermatol 1995;131:157-63.
17. Lautenschlager S, Wulf HC, Pittelkow MR. Photoprotection. Lancet 2007;370:528-37.
18. Gallagher RP, Hill GB, Bajdik CD, et al. Sunlight exposure, pigmentation factors, and risk of nonmelanocytic skin cancer. II. Squamous cell carcinoma. Arch Dermatol 1995;131:164-9.
19. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 2006;53:441-9.
20. Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry-history, content, quality and use. Dan Med Bull 1997;44:535-9.
21. Litt JZ. Drug eruption reference manual. 8th ed. London: The Parthenon Publishing Group; 2002.
22. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997;44:445-8.
23. Kuendgen A, Gattermann N. Valproic acid for the treatment of myeloid malignancies. Cancer 2007;110:943-54.
24. Mongan NP, Gudas LJ. Valproic acid, in combination with all-trans retinoic acid and 5-aza-2′-deoxycytidine, restores expression of silenced RARβ2 in breast cancer cells. Mol Cancer Ther 2005;4:477-86.
25. Lerche CM, Philipsen PA, Sehested M, Wulf HC. Photocarcinogenesis of topical tazarotene and isotretinoin alone and in combination with valproic acid in hairless mice. Exp Dermatol 2008;17:972-4.
26. Jensen AO, Olesen AB, Dethlefsen C, Sorensen HT, Karagas MR. Chronic diseases requiring hospitalization and risk of non-melanoma skin cancers - a population based study from Denmark. J Invest Dermatol 2008;128:926-31.
27. Frentz G, Olsen JH. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 1999;140:237-42.
28. Frisch M, Melbye M. New primary cancers after squamous cell skin cancer. Am J Epidemiol 1995;141:916-22.
29. Frisch M, Hjalgrim H, Olsen JH, Melbye M. Risk of subsequent cancer after diagnosis of basal-cell carcinoma. A population-based, epidemiologic study. Ann Intern Med 1996;125:815-21.
30. Green A, van der Pols J, Hunter D. Skin cancer. In: Adami HO, Hunter D, Trichopolous D, editors. Textbook of cancer epidemiology. Oxford: Oxford University Press; 2008, p. 379.